| 摘要 |
Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds hav e a first peptide chain R1 and a second peptide chain R2, wherein R1 and R2 ma y be the same or different, and are linked through a linking moiety. R1 is approximately 10 to 40 amino acid residues in length and comprises the sequence X3X4X5GPX6TX7X8X9 (SEQ ID NO: 1) wherein X3 is C or Hoc, X4 is R, H , L or W, X5 is M, F, I or nor-leucine (J), X6 is any one of the 20 geneticall y coded L-amino acids or J, X7 is W, 1-naphthylalanine (B) or 2-naphthylalanin e (U), X8 is D, E, I, L or V, and X9 is C or Hoc. Similarly, R2 comprises the sequence X'3X'4X'5GPX'6TX'7X'8X'9 (SEQ ID NO: 2) wherein X'3 is C or Hoc, X' 4 is R, H, L or W, X'5 is M, F, I or J, x'6 is any one of the 20 genetically coded L-amino acids or J, X'7 is W, B or U, X'8 is D, E, I, L or V and X'9 i s C or Hoc. Methods for synthesizing the compounds are provided as well, as ar e pharmaceutical compositions and methods of use.
|
